Patents Assigned to Institute of Materia Medica, Chinese Academy of Medical
Sciences
-
Publication number: 20200181115Abstract: Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.Type: ApplicationFiled: May 23, 2017Publication date: June 11, 2020Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Zhiqiang Feng, Xiaoguang Chen, Yang Yang, Fangfang Lai
-
Patent number: 10611852Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.Type: GrantFiled: February 13, 2018Date of Patent: April 7, 2020Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
-
Publication number: 20200055819Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.Type: ApplicationFiled: May 23, 2017Publication date: February 20, 2020Applicants: Institute of Materia Medica, Chinese Academy of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co., LTDInventors: Zhiqiang Feng, Xiaoguang Chen, Yang Yang, Yi Zheng, Fangfang Lai, Ming Ji, Chuan Zhou, Lijing Zhang, Ke Wang, Nina Xue, Ling Li
-
Patent number: 10174033Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.Type: GrantFiled: December 10, 2009Date of Patent: January 8, 2019Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
-
Patent number: 9393277Abstract: The present invention discloses an Albizzia chinensis extract used in the preparation of a drug for the treatment of gastric ulcers. Specifically, it discloses an Albizzia chinensis (Osbeck) Merr extract and its preparation method including the stems bark of Albizzia chinensis was successively grounded, extracted, concentrated and purificated, as well as a pharmaceutical composition comprising the Albizzia chinensis extract. Through pharmacological test, it has been demonstrated that, the Albizzia chinensis extract showed strong inhibition activity against proton pumps, and it can be used for the treatment of gastric ulcers, chronic gastritis and other acid-related diseases, and its anti-ulcer effect is significant, quick, safe and reliable.Type: GrantFiled: October 24, 2012Date of Patent: July 19, 2016Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Shishan Yu, Jianjun Zhang, Shuanggang Ma, Ruiming Xu, Chengxue Ji
-
Patent number: 9266897Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.Type: GrantFiled: October 24, 2012Date of Patent: February 23, 2016Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Hailin Qin, Wenjie Wang, Zhihui Zhang, Lianqiu Wu, Anjun Deng, Jinqian Yu, Zhihong Li
-
Patent number: 9206405Abstract: A novel glycosyl hydrolase with activities of beta-xylosidase and beta-glucosidase is provided. Said glycosyl hydrolase can convert 7-xylosyltaxane compounds to 7-hydroxyltaxane compounds.Type: GrantFiled: April 12, 2011Date of Patent: December 8, 2015Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Ping Zhu, Haili Cheng, Ruiyu Zhao, Kedi Cheng, Huixia He, Chao Meng, Huixin Zhu
-
Publication number: 20150031717Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.Type: ApplicationFiled: October 24, 2012Publication date: January 29, 2015Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Hailin Qin, Wenjie Wang, Zhihui Zhang, Lianqiu Wu, Anjun Deng, Jinqian Yu, Zhihong Li
-
Publication number: 20140323501Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.Type: ApplicationFiled: July 5, 2012Publication date: October 30, 2014Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
-
Patent number: 8765695Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.Type: GrantFiled: December 25, 2007Date of Patent: July 1, 2014Assignees: Jecui Health Industry Corp. Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Juntian Zhang, Shifeng Chu
-
Publication number: 20130338064Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.Type: ApplicationFiled: July 14, 2011Publication date: December 19, 2013Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
-
Patent number: 8399511Abstract: Two crystalline forms of pinocembrin of formula (I): ? and ?, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.Type: GrantFiled: November 13, 2008Date of Patent: March 19, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Guanhua Du, Yang Lv, Song Wu, Ke Wang, Ying Chang, Zhihong Yang, Yuanfeng Tong, Mei Gao
-
Method for resolution of a mixture of pinocembrin optical isomers, especially a pinocembrin racemate
Patent number: 8399691Abstract: The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.Type: GrantFiled: November 7, 2008Date of Patent: March 19, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Song Wu, Guanhua Du, Yue Yuan, Qingyun Yang, Mei Gao, Yan Qi, Yuanfeng Tong, Yuehua Wang -
Publication number: 20130045942Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.Type: ApplicationFiled: December 10, 2009Publication date: February 21, 2013Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
-
Patent number: 8338401Abstract: The present invention relates to novel coumarin derivatives, their carboxamides, pharmaceutical compositions containing them and their uses as drugs for kidney protection, treating drugs of hypertension, cardio-cerebrovascular diseases, non-insulin dependent diabetes, tumor, pre-cancerous lesion, and edemas.Type: GrantFiled: December 5, 2003Date of Patent: December 25, 2012Assignee: Institute of Materia Medica Chinese Academy of Medical SciencesInventors: Shiping Xu, Xiaoguang Chen, Song Xu, Lanmin Li, Longfei Xie, Hongyan Li, Yan Li, Guifang Cheng
-
Publication number: 20110130352Abstract: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 1-4 in preparing hypoglycemic agents.Type: ApplicationFiled: August 22, 2007Publication date: June 2, 2011Applicant: Institute of Materia Medica Chinese Academy of Medical SciencesInventors: Yuling Liu, Zhufang Shen, Zhen Chen, Renyun Wang, Xuejun Xia, Yueteng Chen, Quan Liu, Sujuan Sun, Mingzhi Xie
-
Publication number: 20110034403Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: December 25, 2007Publication date: February 10, 2011Applicant: INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Juntian Zhang, Shifeng Chu
-
Patent number: 7557089Abstract: The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by ?-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.Type: GrantFiled: December 31, 2003Date of Patent: July 7, 2009Assignee: Institute of Materia Medica, Chinese Academy of Medical ScienceInventors: Jianjun Zhang, Jiangong Shi, Yafang Wang, Dan Zhang, Mei Gao, Yongchun Yang, Shengyang Huang
-
Patent number: 7550507Abstract: The invention relates to new synthetic 2-(?-hydroxypentyl) benzoates, their preparation and pharmaceutical compositions containing such salts as active ingredients. The invention also relates to the use of the compounds for preventing and treating cardioischemia, cerebroischemia and cardiac or cerebral arterial occlusion (obstruction), etc.Type: GrantFiled: May 9, 2002Date of Patent: June 23, 2009Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Jinghua Yang, Xiaoliang Wang, Zhibin Xu, Ying Peng
-
Patent number: 6787564Abstract: The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.Type: GrantFiled: March 26, 2002Date of Patent: September 7, 2004Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Juntian Zhang, Liang Huang, Kemei Wu, Shiming Chen